Alnylam
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
100-102 Avenue De Suffren, Paris, Ile-de...Website
www.alnylam.frRevenue
$34 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Alnylam
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" stratRead more
Popular SearchesAlnylamSIC Code 28,283NAICS Code 32,325Show moreAlnylam Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alnylam your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Alnylam launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Alnylam recently announced quarterly report
Alnylam, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Alnylam has new funding data
Check if Alnylam has recently received funding, and reach out quickly before it becomes old news!
Click to see if Alnylam had a recent Job posting/layoffs
Check out if Alnylam is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Alnylam
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Alnylam is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alnylam is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alnylam.
Alnylam Tech Stack
A closer look at the technologies used by Alnylam
See more technologies
Alnylam News & Media
Alnylam Pharmaceuticals, Inc. (ALNY) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Bank of America Global Healthcare Conference 2026 May 13, 2026 1:40 PM EDTCompany ParticipantsJeffrey Poulton - CFO...Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call Transcript
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2026 Earnings Call April 30, 2026 8:30 AM EDTCompany ParticipantsChristine Lindenboom - Chief Corporate...Alnylam Pharmaceuticals Q1 Earnings Call Highlights
Alnylam Pharmaceuticals (NASDAQ:ALNY) reported what executives described as a strong start to 2026, driven by continued momentum in its transthyretin (TTR) amyloidosis franchise and sustained performance in its rare disease portfolio. On the company’s first-quarter earnings call, CEO Yvonne GreenstrAlnylam Pharmaceuticals (ALNY) Achieved Free Cash Flow Breakeven in 2025
ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Large Cap Growth Strategy”. A copy of the letter can be downloaded here. Following the outbreak of the Middle East conflict, the market experienced a significant decline in growth stocks, resulting in substantial losses. In the quarter, the S&P 500 Index fell 4.3% […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alnylam
Sign Up For FreeTo access detailed company insights
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics r... Read More
